News and Resources

Choose an area of interest:

Eosinophilic Asthma Epileptic Encephalopathy Company News

03.20.19

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma

Discover this News

09.08.18

Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases

Discover this News

05.10.18

Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood

Discover this News

01.01.18

American Society of Hematology: “Dexpramipexole as an oral steriod-sparing agent in hypereosinophilic syndromes”

Discover this News

09.06.17

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Discover this News

1 2

Knopp Disclaimer

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.